Israel's Teva Plunges on Opioid Settlement, Bezeq on Write-off Woes
Investors fear the drugmaker will pay billions for its alleged role in the U.S. opioid epidemic, while the communications giant has been stung by losses at its satellite TV unit
Teva Pharmaceutical
Teva to Pay Oklahoma $85 Million in Opioid Lawsuit
Settlement reached days before company was set to face trial
Billionaire Buffett Has Probably Taken $213 Million Loss on His Teva Stock
Legendary investor had 3.9% stake in drug marker at end of first quarter
Analysis Teva’s Legal Woes Threaten Its Ability to Repay Heavy Debt
The drug maker not only faces price-fixing allegations in the U.S. but also is a party to a suit on opiod abuse
Teva Loses Status as Biggest Firm on TASE as Israelis Sue Too
Israeli institutional investors seeking class action in the U.S. estimate that price-fixing inflated Teva's profits by $2.3 billion
Analysis The Price-fixing Claims Look Worse for Teva Than They Really Are
It’s a nasty business but the financial impact on Teva is containable and the bigger picture for the troubled drug maker is looking brighter
40 U.S. States Sue Teva, Other Drugmakers for 'Multi-billion Dollar Fraud on the American People'
'We all wonder why the prices for generic prescription drugs are so expensive – this is a big reason why,' Connecticut attorney general says, alleging price-fixing conspiracy
Teva Tumbles at Tel Aviv Opening Following Massive U.S. Lawsuit
40 U.S. states sue Teva, other drugmakers for 'multi-billion dollar fraud on the american people'
Israel's Teva Sees Sharp Rise in Revenue Next Year Boosted by New Migraine Drug
Israeli drug maker reports better-than-expected quarterly rules, but shares post a drop anyhow
Israel's Teva Halts Testing Alternative Use for Migraine Drug
The world’s largest generic drug company was counting on the drug Ajovy to help revive it after 2018 debt crisis
Israel's Largest Venture Capital Firm to Focus on Health Care
Named aMoon2 and led by Marius Nacht and Dr. Yair Schindel, the company has $660 million to invest
Opioid Suits Against Sackler Family's Purdue May Cost Teva Up to $3 Billion
Purdue Pharma said to be exploring bankruptcy filing as litigation pressures mount
Business in Brief: Drone Maker Aeronautics Signs Deal to Be Sold to Rafael, Avihai Stolero
Housing & Construction reaches agreement to buy American builder ■ Teva reaches settlement with U.S. on ‘pay-for-delay’ drug deals ■ Delek in advanced talks to sell Phoenix to U.S. fund Centerbridge ■ Bezeq and B Comm pace gains for Tel Aviv shares
Teva CEO: Company Would Have Gone Bankrupt Without Layoffs
After having to layoff 1,350 workers in Israel, Kare Schultz describes crisis of the pharmaceutical company which suffered from dropping generic sales in the U.S. market
Business in Brief: TASE CEO Says Government Is Undercutting Capital Markets
Tel Aviv shares mark their fifth rise in last six sessions ■ Buffet’s Berkshire Hathaway sees Teva holding lose $264 million in value ■ Ratio Petroleum soars on start of Guyana oil exploration ■ Plus500 admits to typo that misled investors about losses
Business in Brief: Bezeq to Petition Court on Merging Units
Plantext to be first Israeli cannabis company to be traded overseas ■ Stanley Fischer hired to advise BlackRock ■ Wall Street weighs down Tel Aviv shares
Business in Brief: Super Pharm Gearing Up for Tel Aviv Stock Exchange IPO
Tel Aviv shares end higher, despite Teva Pharmaceuticals selloff ■ Bondholders backing alternative to Africa Properties
Teva Shares Take Tumble After Warning of Bleak 2019
Israeli drug maker sees a repeat this year of the tough market conditions of 2018
Teva Selling Northern Israeli Plant to FIMI Fund for $45 Million
The sale of the Kiryat Shmona facility was made possible by a collective labor agreement between Teva and the 170 plant workers
Business in Brief: Tel Aviv Shares Eke Out Gains as Energy Shares Rally
Teva migraine drug fails to win coverage by major pharma benefit manager ■ S&P affirms Israel’s credit rating despite fiscal setbacks
Teva’s Generic EpiPen U.S. Launch Still Stalled Five Months After Approval
Short supply is missed opportunity for Israeli drug maker in $750 million market
Major U.S. Drugstore CVS to Cover Migraine Drugs From Teva
CVS Health Corp has decided to add migraine drugs from Teva and Eli Lily and Co to its list of covered drugs, excluding Amgen Inc whose shares have recently fallen
Business in Brief: Pharma Shares Take Tel Aviv Stock Exchange Higher
Shari Arison sells Israeli salt monopoly to Fortissimo fund ■ Five companies weighing bids to set up small-business lender
Business in Brief: Tel Aviv Shares Post Fourth Straight Rise
Teva CEO Schultz says company’s key U.S. generics market has stabilized ■ Naphtha to make tender offer for Isramco ■ Current, former Aeronautics executives suspected of insider trading
Business in Brief: Teva Threatened With Strike at Main Plant for Making Top-selling Copaxone Drug
Two reach plea deal in fraud case ■ Brookland’s controlling shareholder quits ■ Radware buys Indian company ■ stocks extend gains
Business in Brief: Tel Aviv Shares Quietly Mark End of Stormy Year
Teva said to be in talks to sell Oncotest diagnostics unit ■ Africa Israel bailout collapses as Moti Ben-Moshe asks for deposit back
Business in Brief: Dollar at Two-year High Versus Shekel
Teva shareholders demand company sue U.S. employees over role in alleged cartel ■ Tel Aviv shares ride back of Wall Street rebound as China trade fears ease
Teva Suspected of Being Part of a Cartel in U.S. Engaged in Price-fixing and Dividing Market for Generics
The Israeli generics manufacturer is one of 16 drug firms under investigation over purported price-fixing involving 300 medications
Business in Brief: Teva Patent Dispute With Swiss Firm Reaches U.S. Supreme Court
Warburg Pincus in talks with Allied Holding to sell it Leumi Card stake ■ Corning reportedly in talks to buy Israel’s Teldor Cables ■ Taptica shares plunge after CEO quits following fraud ruling ■ Tel Aviv shares fall as optimism on U.S.-China trade ebbs
Teva Shares Rally, Forecast 'Very Strong Launch' for Long-awaited Ajovy Migraine Treatment
The company added that it expected to launch its generic version of the best-selling EpiPen allergy treatment in the current quarter